Skip to content
Open access

Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

Sep 2026 · Alzheimer's & Dementia · Vol 22 · 1 citation · 32 references
Medicine

Abstract

Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision.

Read PDF

Similar papers

Review Open access Sep 2026

More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.

O. Langford, R. Raman, P. Aisen et al. · 1 citation
Open access Sep 2026

Transcriptional risk score for chronic kidney disease: relation to Alzheimer's disease

The impact of CKD transcriptional risk on AD endophenotypes is assessed by assessing the impact of CKD transcriptional risk on AD endophenotypes in individuals with chronic kidney disease.

Jung-Min Pyun, Young Ho Park, Jiyun Hwang et al. · 0 citations
Open access Sep 2026

Evaluating the 8‐Year Association Between Cognition and Beta Amyloid in the Dallas Lifespan Brain Study Cohort

Mounting evidence suggests beta amyloid (Aβ) is not the sole initiating driver of cognitive decline in Alzheimer's disease (AD). This study explores whether there is an association between cognitive decline over eight years and Aβ.

J. David, Isabella Torres, Evan Smith et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.